Incyte Corporation (INCY) — ESG & Values Scores

Environment story

Incyte discloses no Scope 1, Scope 2, or Scope 3 emissions data in available filings. No net-zero target, renewable energy commitment, or environmental sustainability initiatives are documented. No material environmental controversies identified in source materials. The absence of substantive environmental reporting and climate commitments results in a below-median ESG score for the pharmaceutical sector. Greenwashing risk moderate: no claimed emissions reductions to verify; no net-zero aspirations publicized.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

No disclosed initiatives on file for this pillar.

Social story

Incyte does not disclose CEO-to-median-worker pay ratio, workforce diversity metrics (gender, race), or turnover rates in proxy or 10-K filings examined. No union agreements, NLRB complaints, or labor disputes documented in recent filings. No supply-chain human rights audits or controversies disclosed. The company maintains a patient assistance program and conducts some compliance reviews, but comprehensive DEI and social governance data are not publicly available. Social score reflects lack of substantive disclosure rather than positive or negative findings.

Criticisms on file

Speaker programs and patient assistance programs subject to prior inquiry
Source: INCY_10k.txt - Item 1A Risk Factors, Healthcare Compliance

Disclosed initiatives

Patient Assistance Programs

Company-sponsored programs providing financial assistance to eligible patients with no insurance or underinsured status.
Compliance and Governance Review

Periodic review of management efforts to monitor compliance with programs and policies designed to promote adherence to applicable laws and regulations.

Governance story

Board independence estimated at 88% (7 of 8 non-employee directors; employee CEO excluded). No dual-class share structure identified. Lobbying expenditures not quantified in filings. No active antitrust litigation, material SEC consent decrees, or consumer-safety proceedings disclosed. Company faces litigation with CMS regarding Medicaid rebate definition for OPZELURA (accrual $218.5M as of Dec 31, 2025); patent infringement litigation against generic manufacturers ongoing but routine for pharma. Governance score reflects strong board structure offset by unquantified lobbying exposure and litigation-related uncertainties.

Criticisms on file

CMS Medicaid Rebate Litigation—OPZELURA 'Line Extension' Classification
Source: INCY_10k.txt - MD&A, Revenue Recognition; INCY_10k.txt - Item 1A Risk Factors, Healthcare Reform
Patent Infringement Litigation—JAKAFI Generic Challenges
Source: INCY_10k.txt - Item 1A Risk Factors, Competition. Multiple ANDA and 505(b)(2) challenges filed by Apotex, Hikma, Sun Pharma, Granules, Dr. Reddy's, Eugia Pharma. Settlements reached with Hikma (Oct 2025) and Granules (Feb 2026). Actions against Apotex, Sun Pharma, Dr. Reddy's remain pending.
Patent Infringement Litigation—OPZELURA Generic Challenges
Source: INCY_10k.txt - Item 1A Risk Factors, Competition. ANDAs filed by Padagis, Taro, Zydus, Encube targeting ruxolitinib phosphate cream formulation patents (expiring 2031, 2040). Patent infringement actions filed in U.S. District Court for District of New Jersey. Litigation pending.

Disclosed initiatives

Board Independence and Committee Structure

Eight-member Board with seven independent directors; all committee members determined independent per Nasdaq/SEC standards. Four standing committees: Audit and Finance, Compensation, Nominating and Corporate Governance, Science and Technology.

Governance structure aligns with institutional best practices.
Annual Director Compensation Review

Compensation Committee with independent consultant reviews non-employee director compensation against peer group annually. Effective Jan 1, 2026: annual retainer increased to $65,000; Board Chair retainer increased to $130,000.

Transparent market-based director compensation adjustment process.
Compliance and Risk Management Oversight

Audit and Finance Committee reviews enterprise risk assessment and management practices, including financial, operating, cybersecurity and IT risks, and compliance with applicable laws and regulations.

Established oversight framework for regulatory and operational risks.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Incyte Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Incyte Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)